Immunophilins and cardiovascular complications

Current Medicinal Chemistry

Volumn 18, Issue 35, 2011, Pages 5408-5413

  Calderon Sanchez E ^a   Rodriguez Moyano, M ^a   Smani, T ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Atherosclerosis; Cardioprotection; Immunophilins; Remodelling

Indexed keywords

CALCINEURIN; CAVEOLIN; CHOLESTEROL; CYCLOPHILIN D; CYCLOSPORIN A; FK 506 BINDING PROTEIN; INOSITOL TRISPHOSPHATE 3 KINASE; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; RAPAMYCIN; RYANODINE RECEPTOR; TACROLIMUS;

ATHEROSCLEROSIS; BRAIN; CALCIUM SIGNALING; CARDIOVASCULAR DISEASE; ENZYME ACTIVITY; GENETIC TRANSCRIPTION; HEART; HEART ARRHYTHMIA; HEART FAILURE; HEART PROTECTION; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; INTRACELLULAR SIGNALING; KIDNEY; LIVER; LUNG; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN TARGETING; PROTEIN TRANSPORT; REVIEW; STENOSIS;

ANIMALS; CALCIUM SIGNALING; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; CAVEOLINS; CHOLESTEROL; HUMANS; IMMUNOPHILINS; IMMUNOSUPPRESSIVE AGENTS;

EID: 82255167630     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711798194379     Document Type: Review

References (76)

1. Marks, A. R. Cellular functions of immunophilins. Physiol. Rev., 1996, 76, 631-649. (Pubitemid 26286074)
2. Gothel, S. F.; Marahiel, M. A. Peptidyl-prolyl cis-trans isomerases, a superfamily of ubiquitous folding catalysts. Cell. Mol. Life. Sci., 1999, 55, 423-436. (Pubitemid 29178881)
3. Galat, A. Peptidylprolyl cis/trans isomerases (immunophilins): biological diversity-targets-functions. Curr. Top. Med. Chem., 2003, 3, 1315-47.
4. Adams, B.; Musiyenko, A.; Kumar, R.; Barik, S. A novel class of dualfamily immunophilins. J. Biol. Chem., 2005, 280, 24308-24314.
5. Chang, J. Y.; Sehgal, S. N.; Bansbach, C. C. FK506 and rapamycin: novel pharmacological probes of the immune response. Trends. Pharmacol. Sci., 1991, 12, 218-223.
6. Morris, R. E. Rapamycin: FK506's fraternal twin or distant cousin? Immunol. Today. 1991, 12, 137-140.
7. Kunz, J.; Hall, M. N. Cyclosporin A, FK506 and rapamycin: more than just immunosuppression. Trends. Biochem. Sci., 1993, 18, 334-38. (Pubitemid 23258290)
8. Satoh, K.; Shimokawa, H.; Berk, B. C. Cyclophilin A: promising new target in cardiovascular therapy. Circ. J., 2010, 74, 2249-2256.
9. Nigro, P.; Satoh, K.; O'Dell, M. R.; Soe, N. N.; Cui, Z.; Mohan. A.; Abe, J.; Alexis. J. D.; Sparks. J. D.; Berk, B. C. Cyclophilin A is an inflammatory mediator that promotes atherosclerosis in apolipoprotein E-deficient mice. J. Exp. Med., 2011, 208, 53-66.
10. Zhang, W.; Li, J. L.; Hosaka, M.; Janz, R.; Shelton, J. M.; Albright, G. M.; Richardson, J. A.; Südhof, T. C.; Victor, R. G. Cyclosporine A-induced hypertension involves synapsin in renal sensory nerve endings. Proc. Natl. Acad. Sci. U S A., 2000, 97, 9765-9770. (Pubitemid 30650850)
11. Zhong, J.; Chen, J.; Cao, T.; Wang, L.; Zhang, W.; Liu, D.; Zhu, Z. Adenovirus-mediated FKBP12.6 overexpression induces hypertrophy and apoptosis in cultured neonatal cardiomyocytes. Clin. Exp. Pharmacol. Physiol., 2009, 36, 135-140.
12. Davis, T. L.; Walker, J. R.; Campagna-Slater, V.; Finerty, P. J.; Paramanathan, R.; Bernstein, G.; MacKenzie, F.; Tempel, W.; Ouyang, H.; Lee, W. H.; Eisenmesser, E. Z.; Dhe-Paganon, S. Structural and Biochemical Characterization of the Human Cyclophilin Family of Peptidyl-Prolyl Isomerases. PLoS. Biol., 2010, 8: e1000439
13. Gething, M. J.; Sambrook, J. Protein folding in the cell. Nature, 1992, 355, 33-45.
14. Cardenas, M. E.; Zhu, D.; Heitman, J. Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin. Curr. Opin. Nephrol. Hypertens., 1995, 4, 472-477. (Pubitemid 26024687)
15. Pan, H.; Luo, C.; Li, R.; Qiao, A.; Zhang, L.; Mines, M.; Nyanda, A. M.; Zhang, J.; Fan, G. H. Cyclophilin A is required for CXCR4-mediated nuclear export of heterogeneous nuclear ribonucleoprotein A2, activation and nuclear translocation of ERK1/2, and chemotactic cell migration. J. Biol. Chem., 2008, 283, 623-637.
16. Zhu, C.; Wang, X.; Deinum, J.; Huang, Z.; Gao, J.; Modjtahedi, N.; Neagu, M. R.; Nilsson, M.; Eriksson, P. S.; Hagberg, H.; Luban, J.; Kroemer, G.; Blomgren, K. Cyclophilin A participates in the nuclear translocation of apoptosis-inducing factor in neurons after cerebral hypoxia-ischemia. J. Exp. Med., 2007, 204, 1741-1748. (Pubitemid 47236312)
17. Uittenbogaard, A.; Ying, Y.; Smart, E. J. Characterization of a cytosolic heatshock protein-caveolin chaperone complex. Involvement in cholesterol trafficking. J. Biol. Chem., 1998, 273, 6525-6532. (Pubitemid 28144750)
18. Fujimura, A.; Michiue, H.; Nishiki, T.; Ohmori, I.; Wei, F. Y.; Matsui, H.; Tomizawa, K. Expression of a constitutively active calcineurin encoded by an intron-retaining mRNA in follicular keratinocytes. PLoS. One., 2011, 6, e17685.
19. Krummrei, U.; Bang, R.; Schmidtchen, R.; Brune, K.; Bang, H. Cyclophilin - A is a zinc-dependent DNA binding protein in macrophages. FEBS. Lett., 1995, 371, 47-51.
20. Rosado, J. A.; Pariente, J. A.; Salido, G. M.; Redondo, P. C. SERCA2b activity is regulated by cyclophilins in human platelets. Arterioscler. Thromb. Vasc. Biol., 2010, 30, 419-425.
21. Bergsma, D. J.; Eder, C.; Gross, M.; Kersten, H.; Sylvester, D.; Appelbaum, E.; Cusimano, D.; Livi, G. P.; McLaughlin, M. M.; Kasyan, K. The cyclophilin multigene family of peptidyl-prolyl isomerases: Characterization of three separate human isoforms. J. Biol. Chem., 1991, 266, 23204-23214. (Pubitemid 21908781)
22. 2+ homeostasis after ER stress. J. Cell. Sci., 2008, 121, 3636-3648.
23. Baines, C. P.; Kaiser, R. A.; Purcell, N. H.; Blair, N. S.; Osinska, H.; Hambleton, M. A.; Brunskill, E. W.; Sayen, M. R.; Gottlieb, R. A.; Dorn, G. W.; Robbins, J.; Molkentin, J. D. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature, 2005, 434, 658-662. (Pubitemid 40488559)
24. 2+ exchange, metabolic flexibility, and propensity for heart failure in mice. J. Clin. Invest., 2010, 120, 3680-3687.
25. Cameron, A. M.; Steiner, J. P.; Sabatini, D. M.; Kaplin, A. I.; walensky, L. D.; Snyder, H. Immunophilin FK506 binding protein associated with inositol 1, 4, 5-triphosphate receptor modulates calcium flux. Proc. Natl. Acad. Sci. USA., 1995, 92, 1784-1788.
26. 2+ release and contraction in pulmonary artery myocytes. Cell Calcium, 2004, 35, 345-355. (Pubitemid 38351203)
27. Chelu, M. G.; Danila, C. I.; Gilman, C. P.; Hamilton, S. L. Regulation of ryanodine receptors by FK506 binding proteins. Trends. Cardiovasc. Med., 2004, 14(6), 227-234. (Pubitemid 39297020)
28. Harding, M. W.; Galat, A.; Uehling, D. E.; Schreiberg, S. L. A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature. 1989, 341, 758-760. (Pubitemid 19260893)
29. Liu, J.; Farmer, J. D.; Lane, W. S.; Friedman, J.; Weissman, I.; Schreiber, S. L. Calcineurin is a common target of cyclophilin-cylcosporin A and FKBP-FK506 complexes. Cell, 1991, 66, 807-815. (Pubitemid 121001714)
30. 2+ release by mTOR and calcineurin. J. Cell. Sci., 2005;118, 5443-5451. (Pubitemid 43079286)
31. Tang, W. X.; Chen, Y. F.; Zou, A. P.; Campbell, W. B.; Li, P. L. Role of FKBP12.6 in cADPR-induced activation of reconstituted ryanodine receptors from arterial smooth muscle. Am. J. Physiol. Heart. Circ. Physiol., 2002, 282(4), H1304-H1310. (Pubitemid 34654882)
32. 2+ release in colonic but not aortic smooth muscle. Cell Calcium, 2008, 43, 539-549. (Pubitemid 351663984)
33. 2+ release from sarcoplasmic reticulum in vascular smooth muscle: the role of FK506 binding proteins and mTOR. B r. J. Pharmacol., 2009, 158, 1112-1120.
34. Libby, P. Inflammation in atherosclerosis. Nature. 2002, 420, 868-874. (Pubitemid 36019640)
35. Kockx, M.; Jessup, W.; Kritharides, L. Cyclosporin A and atherosclerosis: cellular pathways in atherogenesis. Pharmacol. Ther., 2010, 128, 106-118.
36. Satoh, K.; Nigro, P.; Matoba, T.; O'Dell, M. R.; Cui, Z.; Shi, X.; Mohan, A.; Yan, C.; Abe, J.; Illig, K. A.; Berk, B. C. Cyclophilin A enhances vascular oxidative stress and the development of angiotensin II-induced aortic aneurysms. Nat. Med., 2009, 15, 649-656.
37. Sherry, B.; Yarlett, N.; Strupp, A.; Cerami, A. Identification of cyclophilin as a proinflammatory secretory product of lipopolysaccharide- activated macrophages. Proc. Natl. Acad. Sci. USA., 1992, 89, 3511-3515.
38. Coppinger, J. A.; Cagney, G.; Toomey, S.; Kislinger, T.; Belton, O.; McRedmond, J. P.; Cahill, D. J.; Emili, A.; Fitzgerald, D. J.; Maguire, P. B. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood, 2004, 103, 2096-2104. (Pubitemid 38326225)
39. Jin, Z. G.; Lungu, A. O.; Xie, L.; Wang, M.; Wong, C.; Berk, B. C. Cyclophilin A is a proinflamatory cytokine that activates endothelial cells. Arterioscler. Thromb. Vasc. Biol., 2004, 24, 1186-1191. (Pubitemid 38880006)
40. Kim, S. H.; Lessner, S. M.; Sakurai, Y.; Galis, Z. S. Cyclophilin A as a novel biphasic mediator of endothelial activation and dysfunction. Am. J. Pathol., 2004, 164, 1567-1574. (Pubitemid 38529759)
41. Taniyama, Y.; Griendling, K. K. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension, 2003, 42, 1075-1081. (Pubitemid 37549058)
42. Griendling, K. K.; FitzGerald, G. A. Oxidative stress and cardiovascular injury: Part II: animal and human studies. Circulation, 2003, 108, 2034-2040. (Pubitemid 37337574)
43. Satoh, K.; Matoba, T.; Suzuki, J.; O'Dell, M. R.; Nigro, P.; Cui, Z.; Mohan, A.; Pan, S.; Li, L.; Jin, Z. G.; Yan, C.; Abe, J.; Berk, B. C. Cyclophilin A mediates vascular remodeling by promoting inflammation and vascular smooth muscle cell proliferation. Circulation, 2008, 117, 3088-3098.
44. Satoh, K.; Nigro, P.; Zeidan, A.; Soe, N. N.; Jaffré, F.; Oikawa, M.; O'Dell, M. R.; Cui, Z.; Menon, P.; Lu, Y.; Mohan, A.; Yan, C.; Blaxall, B. C.; Berk, B. C. Cyclophilin A Promotes Cardiac Hypertrophy in Apolipoprotein E-Deficient Mice. Arterioscler. Thromb. Vasc. Biol., 2011, 31, 1116-1123.
45. Payeli, S. K.; Schiene-Fischer, C.; Steffel, J.; Camici, G. G.; Rozenberg, I.; Lüscher, T. F.; Tanner, F. C. Cyclophilin A differentially activates monocytes and endothelial cells: role of purity, activity, and endotoxin contamination in commercial preparations. Atherosclerosis, 2008, 197, 564-571. (Pubitemid 351417900)
46. Long, C.; Cook, L. G.; Hamilton, S. L.; Wu, G. Y.; Mitchell, B. M. FK506 binding protein 12/12.6 depletion increases endothelial nitric oxide synthase threonine 495 phosphorylation and blood pressure. Hypertension, 2007, 49, 569-576.
47. Xin, H. B.; Senbonmatsu, T.; Cheng, D. S.; Wang, Y. X.; Copello, J. A.; Ji, G. J.; Collier, M. L.; Deng, K. Y.; Jeyakumar, L. H.; Magnuson, M. A.; Inagami, T.; Kotlikoff, M. I.; Fleischer, S. Oestrogen protects FKBP12.6 null mice from cardiac hypertrophy. Nature, 2002, 416, 334-337. (Pubitemid 34260249)
48. Cook, L. G.; Chiasson, V. L.; Long, C.; Wu, G. Y.; Mitchell, B. M. Tacrolimus reduces nitric oxide synthase function by binding to FKBP rather than by its calcineurin effect. Kidney. Int., 2009, 75, 719-726.
49. Satoh, K.; Fukumoto, Y.; Nakano, M.; Sugimura, K.; Nawata, J.; Demachi, J.; Karibe, A.; Kagaya, Y.; Ishii, N.; Sugamura, K.; Shimokawa, H. Statin ameliorates hypoxia-induced pulmonary hypertension associated with downregulated stromal cell-derived factor-1. Cardiovasc. Res., 2009, 81, 226-234.
50. Hayashida, K.; Fujita, J.; Miyake, Y.; Kawada, H.; Ando, K.; Ogawa, S.; Fukuda, K. Bone marrow-derived cells contribute to pulmonary vascular remodeling in hypoxia-induced pulmonary hypertension. Chest, 2005, 127, 1793-1798. (Pubitemid 46218809)
51. Kroemer, G.; Galluzzi, L.; Brenner, C. Mitochondrial membrane permeabilization in cell death. Physiol. Rev., 2007, 87, 99-163. (Pubitemid 46209992)
52. Murphy, E.; Steenbergen, C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol. Rev., 2008, 88, 581-609. (Pubitemid 351520088)
53. Staat, P.; Rioufol, G.; Piot, C.; Cottin, Y.; Cung, T. T.; L'Huillier, I.; Aupetit, J. F.; Bonnefoy, E.; Finet, G.; André-Fouët, X.; Ovize, M. Postconditioning the human heart. Circulation, 2005, 112, 2143-2214.
54. Hausenloy, D. J.; Ong, S. B.; Yellon, D. M. The mitochondrial permeability transition pore as a target for preconditioning and postconditioning. Basic. Res. Cardiol., 2009, 104, 189-202.
55. Nakagawa, T.; Shimizu, S.; Watanabe, T.; Yamaguchi, O.; Otsu, K.; Yamagata, H.; Inohara, H.; Kubo, T.; Tsujimoto, Y. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature, 2005, 434, 652-658. (Pubitemid 40488558)
56. Schinzel, A. C.; Takeuchi, O.; Huang, Z.; Fisher, J. K.; Zhou, Z.; Rubens, J.; Hetz, C.; Danial, N. N.; Moskowitz, M. A.; Korsmeyer, S. J. Cyclophilin D is a component of mitochondrial permeability transition and mediates neuronal cell death after focal cerebral ischemia. Proc. Natl. Acad. Sci. USA., 2005, 102, 12005-12010. (Pubitemid 41291119)
57. Javadov, S.; Karmazyn, M.; Escobales, N. Mitochondrial permeability transition pore opening as a promising therapeutic target in cardiac diseases. J. Pharmacol. Exp. Ther., 2009, 330, 670-678.
58. Giorgio, V.; Soriano, M. E.; Basso, E.; Bisetto, E.; Lippe, G.; Forte, M. A.; Bernardi, P. Cyclophilin D in mitochondrial pathophysiology. Biochim. Biophys. Acta., 2010, 1797, 1113-1118.
59. 2+-induced large-amplitude swelling of liver and heart mitochondria by cyclosporin is probably caused by the inhibitor binding to mitochondrial-matrix peptidyl-prolyl cis-trans isomerase and preventing it interacting with the adenine nucleotide translocase. Biochem. J., 1990, 268, 153-160. (Pubitemid 20166664)
60. Kato, M.; Akao, M.; Matsumoto-Ida, M.; Makiyama, T.; Iguchi, M.; Takeda, T.; Shimizu, S.; Kita, T. The targeting of cyclophilin D by RNAi as a novel cardioprotective therapy: evidence from two-photon imaging. Cardiovasc. Res., 2009, 83, 335-344.
61. Hausenloy, D.; Wynne, A.; Duchen, M. R.; Yellon, D. Transient mitochondrial permeability transition pore opening mediates preconditioning- induced protection. Circulation, 2004, 109, 1714-1717. (Pubitemid 38500671)
62. Hausenloy, D. J.; Lim, S. Y.; Ong, S. G.; Davidson, S. M.; Yellon, D. M. Mitochondrial cyclophilin-D as a critical mediator of ischaemic preconditioning. Cardiovasc. Res., 2010, 88, 67-74.
63. Nishihara, M.; Miura, T.; Miki, T.; Tanno, M.; Yano, T.; Naitoh, K.; Ohori, K.; Hotta, H.; Terashima, Y.; Shimamoto, K. Modulation of the mitochondrial permeability transition pore complex in GSK-3beta-mediated myocardial protection. J. Mol. Cell. Cardiol., 2007, 43, 564-570. (Pubitemid 47615050)
64. Bernardi, P. The permeability transition pore. Control points of a cyclosporin A-sensitive mitochondrial channel involved in cell death. Biochim. Biophys. Acta., 1996, 1275, 5-9. (Pubitemid 26233155)
65. Halestrap, A. P. Calcium, mitochondria and reperfusion injury: a pore way to die. Biochem. Soc. Trans., 2006, 34, 232-237.
66. Di Lisa, F.; Carpi, A.; Giorgio, V.; Bernardi, P. The mitochondrial permeability transition pore and cyclophilin D in cardioprotection. Biochim. Biophys. Acta., 2011, doi:10.1016/j.bbamcr.2011.01.031
67. Cereghetti, G. M.; Stangherlin, A.; Martins, B. O. Dephosphorylation by calcineurin regulates translocation of Drp1 to mitochondria. Proc. Natl. Acad. Sci. USA., 2008, 105, 15803-15808.
68. Kushnir, A.; Marks, A. R. The ryanodine receptor in cardiac physiology and disease. Adv. Pharmacol., 2010, 59, 1-30.
69. Laitinen, P. J.; Brown, K. M.; Piippo, K.; Swan, H.; Devaney, J. M.; Brahmbhatt, B.; Donarum, E. A.; Marino, M.; Tiso, N.; Viitasalo, M.; Toivonen, L.; Stephan, D. A.; Kontula, K. Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia. Circulation, 2001, 103, 485-490. (Pubitemid 32116230)
70. Lehnart, S. E.; Wehrens, X. H.; Laitinen, P. J.; Reiken, S. R.; Deng, S. X.; Cheng, Z.; Landry, D. W.; Kontula, K.; Swan, H.; Marks, A. R. Sudden death in familial polymorphic ventricular tachycardia associated with calcium release channel (ryanodine receptor) leak. Circulation, 2004, 109, 3208-3214.
71. Brillantes, A. B.; Ondrias, K.; Scott, A.; Kobrinsky, E.; Ondriasová, E.; Moschella, M. C.; Jayaraman, T.; Landers, M.; Ehrlich, B. E.; Marks, A. R. Stabilization of calcium release channel (ryanodine receptor) function by FK506-binding protein. Cell, 1994, 77, 513-523. (Pubitemid 24153992)
72. i transient in rat cardiac myocytes. Am. J. Physiol. Heart. Circ. Physiol., 2004, 22, H1987-H1993. (Pubitemid 39430734)
73. Zhong, J.; Chen, J.; Cao, T.; Wang, L.; Zhang, W.; Liu, D.; Zhu, Z. Adenovirus-mediated FKBP12.6 overexpression induces hypertrophy and apoptosis in cultured neonatal cardiomyocytes. Clin. Exp. Pharmacol. Physiol., 2009, 36, 135-140.
74. 2+-release channels from cardiac muscle. Circ. Res., 1996, 78, 990-997.
75. Xin, H. B.; Senbonmatsu, T.; Cheng, D. S.; Wang, Y. X.; Copello, J. A.; Ji, G. J.; Collier, M. L.; Deng, K. Y.; Jyakumar, L. H.; Magnuson, M. A.; Inagami, T.; Kotlikoff, M. I.; Fleischer, F. Oestrogen protects FKBP12.6 null mice from cardiac hypertrophy. Nature, 2002, 416, 334-338.
76. Maruyama, M.; Li, B. Y.; Chen, H.; Xu, X.; Song, L. S.; Guatimosim, S.; Zhu, W.; Yong, W.; Zhang, W.; Bu, G.; Lin, S. F.; Fishbein, M. C.; Lederer, W. J.; Schild, J. H.; Field, L. J.; Rubart, M.; Chen, P. S.; Shou, W. FKBP12 is a critical regulator of the heart rhythm and the cardiac voltage-gated sodium current in mice. Circ. Res., 2011, 108, 1042-1052.